“…To explore possible mechanisms of the CCC therapeutics for combating pancreatic cancer with ovarian cancer cells, we applied DAVID Bioinformatics 24 and the weighted functional and pathway analysis tool WEAT 25 , through which here we analyzed a number of functional/pathway categories, including ARCHS4 Kinases Coexp, ARCHS4 TFs Coexp, BioPlanet, BioPlex, ClinVar 2019, DisGeNET, DSigDB, GO biological process, GO cellular component, GO molecular function, GWAS Catalog 2019, Human Gene Atlas, Human Phenotype Ontology, Jensen COMPARTMENTS, Jensen DISEASES, KEGG, MSigDB Hallmark 2020, Pfam Domains 2019, Rare Diseases AutoRIF Gene Lists, RNA Seq Disease Gene and Drug Signatures from GEO, and TRANSFAC and JASPAR PWMs. Genes with fold change (FC) >=2.0 or <=0.5 between the pancreatic cancer xenografts with and without SKOV3 treatment as the differentially expressed genes (DEGs).…”